

CONTACT: Brian Bennett
(501)225-9733



(For Immediate Release)

i3 EXPLORES LINK BETWEEN BIPOLAR DISORDER AND LIPID DISORDER AT NCDEU

i3 To Make Seven Presentations at Important Conference

BASKING RIDGE, NJ, June 18, 2009—Pharmaceutical services company i3 announced today that i3 Research will present seven posters at the 49th Annual New Clinical Drug Evaluation Unit meeting (NCDEU), a critical venue for psychopharmacology, to be held June 29-July 2 in Hollywood, FL. Highlights include:

1. *Is the Presence of Bipolar Disorder a Risk Factor for Lipid Disorder?*

People who suffer from bipolar disorder have a higher incidence of lipid disorder. Moss et al. conducted a database study using de-identified health claims from a large US insurer to quantify the association. The authors determined the rates of lipid disorder, thyroid disorder, and diabetes in bipolar patients as compared to a sample of patients who had no diagnosis of a mood or psychotic disorder. They found that patients diagnosed with thyroid disorder or diabetes had similar incidence of lipid disorder whether or not they had a mood disorder. However, those bipolar patients without thyroid disorder or diabetes had a significantly higher likelihood of having lipid disorder than the control group, and that risk increased in males in their 20s and 30s.

Poster Session: Wednesday, 01 July 2009, 12:00 - 2:00 p.m.

2. *The Computerized Neuropsychological Test Battery Discriminates Healthy Elderly, MCI, Mild and Moderate Alzheimer's Disease.*

As new vaccines and compounds to treat Alzheimer's disease (AD) are developed, there is an increased need to precisely distinguish among healthy elderly, those with mild cognitive impairment (MCI), and those with mild and moderate AD. Veroff et al. conducted three separate studies and determined that the computerized neuropsychological test battery (CNTB) was able to differentiate between each of these categories. Two of the studies measured the ability to remember word lists, verbal and visual memory, and attention/concentration. The third, a retrospective study, calculated correlations in the rate of decline of AD patients. Enhanced precision in discrimination among these patient groups has the potential to accelerate the development of AD compounds.

Poster Session: Wednesday, 01 July 2009, 12:00 - 2:00 p.m.

3. *PANSS Training in the Japanese Cohort of an International Schizophrenia Clinical Trial: Inter-Rater Reliability and Culturally Specific Differences in Training and Rating.*

-more-

NCDEU/2

The Positive and Negative Syndrome Scale (PANSS) is often a critical measurement in schizophrenia clinical trials. Language and cultural barriers can affect the training of Japanese PANSS raters, creating challenges for clinical trials in Japan. Adams et al. report the results of a PANSS training program that successfully assessed and addressed language and cultural issues relevant to training Japanese raters. Japanese PANSS raters performed as well as raters from other countries, and new raters added after the investigators' meeting performed as well as those trained at the investigators' meeting.

Poster Session: Wednesday, 01 July 2009, 12:00 - 2:00 p.m.

i3 researchers also will make these presentations:

Development and Psychometric Exploration of a Clinical Global Impression Scale for Schizoaffective Disorder.

Poster Session: Wednesday, 01 July 2009, 12:00 - 2:00 p.m.

Improving ADAS-Cog Sensitivity for Alzheimer's Clinical Trials: Central Rating of Subjective Items.

Poster Session: Tuesday, 30 June 2009, 12:00 - 2:00 p.m.

Selecting the Best Raters for Discriminating Negative and Depressive Symptoms in a Trial with Depressive Schizophrenic Patients.

Poster Session: Wednesday, 01 July 2009, 12:00 - 2:00 p.m.

Central Monitoring: Identifying and Addressing Compensatory Rater Behaviors that Potentially Reduce Outcome Scale Sensitivity in Psychiatric Clinical Trials.

Poster Session: Wednesday, 01 July 2009, 12:00 - 2:00 p.m.

About i3

i3, a global Ingenix company, provides integrated scientific strategies and solutions throughout the pharmaceutical product lifecycle. It is composed of i3 Research, a therapeutically specialized contract research organization; i3 Drug Safety, engaged in pharmacovigilance and epidemiology; i3 Pharma Informatics, a data, science and technology provider of market analytics; i3 Statprobe, a leader in comprehensive data services; i3 Pharma Resourcing, a world-class staffing partner; and i3 Innovus, delivering the science and solutions to achieve marketplace success. i3 helps companies gain sharper insights that lead to better patient care. For more information, visit www.i3global.com.

#